US-based biotech Eikon Therapeutics has raised $350.7m in funding to advance its portfolio of cancer candidates. The company’s lead asset, EIK1001, is a systemically administered Toll-like receptor 7 ...

Investing.com -- Shares of drug developer Eikon Therapeutics (NYSE:EIKN) rose 6% to $14.65 on Monday as at least five Wall Street brokerages initiated coverage with bullish ratings following the end ...

Eikon Therapeutics, the drug discovery startup with a former Merck & Co. research chief at the helm, has appointed a pantheon of biotech veterans on its quest to take its live-cell imaging platform to ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eikon Therapeutics, a well-funded drug startup run by ...

Investing.com -- Eikon Therapeutics Inc. (NASDAQ:EIKN) shares fell 5.7% following Wedbush analyst Robert Driscoll’s initiation of coverage with an Underperform rating and a $7.00 price target.

Biotechnology company Eikon Therapeutics announced the initial closing of a $350.7 million Series D financing round that it will use to advance its clinical-stage programs. The new funding brings the ...

HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics, Inc., which advances breakthrough therapeutics through the purposeful integration of engineering and science, announced today that it has ...